Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.99 USD | -1.00% | 0.00% | -50.94% |
Mar. 25 | 180 Life Sciences Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Mar. 11 | 180 Life Sciences Corp. Announces Board Changes | CI |
Valuation
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | - | - | 76.24 | 132.7 | 6.858 | 2.14 |
Enterprise Value (EV) 1 | - | - | 77.91 | 126.4 | 1.228 | 1.218 |
P/E ratio | - | - | -4.13 x | -6.02 x | -0.17 x | -0.08 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | - | - | -14.1 x | -8.14 x | -0.07 x | -0.09 x |
EV / FCF | - | - | 10,001,386 x | -21,737,542 x | -59,737 x | -200,075 x |
FCF Yield | - | - | 0% | -0% | -0% | -0% |
Price to Book | -5.31 x | 8.66 x | 2.36 x | 3.38 x | 1.12 x | -17 x |
Nbr of stocks (in thousands) | - | - | 73.5 | 89.5 | 106 | 528 |
Reference price 2 | 3,876 | 4,064 | 1,037 | 1,482 | 64.41 | 4.056 |
Announcement Date | 2/10/20 | 10/9/20 | 7/9/21 | 3/31/22 | 3/31/23 | 3/25/24 |
Income Statement Evolution (Annual data)
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -8.721 | -20.79 | -5.523 | -15.53 | -17.79 | -13.37 |
EBIT 1 | -8.744 | -20.86 | -5.648 | -15.64 | -17.9 | -13.48 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -14.5 | -25.4 | -10.9 | -20.35 | -39.67 | -22.28 |
Net income 1 | -14.5 | -25.39 | -10.88 | -20.32 | -38.73 | -19.94 |
Net margin | - | - | - | - | - | - |
EPS | - | - | -251.3 | -246.3 | -387.2 | -52.59 |
Free Cash Flow | - | -3.167 | 7.79 | -5.815 | -20.55 | -6.089 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 2/10/20 | 10/9/20 | 7/9/21 | 3/31/22 | 3/31/23 | 3/25/24 |
Income Statement Evolution (Quarterly data)
Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 |
---|---|---|---|---|---|
Net sales 1 | - | - | - | - | - |
EBITDA | - | - | - | - | - |
EBIT 1 | -4.217 | -4.462 | -3.681 | -4.522 | -4.055 |
Operating Margin | - | - | - | - | - |
Earnings before Tax (EBT) 1 | 18.29 | 1.03 | 1.564 | 2.939 | -21.49 |
Net income 1 | 18.3 | 1.036 | 1.564 | 2.939 | -21.49 |
Net margin | - | - | - | - | - |
EPS 2 | 87.40 | 19.00 | 19.00 | 34.20 | -209.0 |
Dividend per Share | - | - | - | - | - |
Announcement Date | 11/15/21 | 3/31/22 | 5/16/22 | 8/9/22 | 11/10/22 |
Balance Sheet Analysis
Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 3.44 | 1.67 | - | - | - |
Net Cash position 1 | 0.57 | - | - | 6.27 | 5.63 | 0.92 |
Leverage (Debt/EBITDA) | - | -0.1657 x | -0.3029 x | - | - | - |
Free Cash Flow | - | -3.17 | 7.79 | -5.81 | -20.6 | -6.09 |
ROE (net income / shareholders' equity) | - | -164% | -31.6% | -58.4% | -153% | -355% |
ROA (Net income/ Total Assets) | - | -48.9% | -6.57% | -16.5% | -27.2% | -67.6% |
Assets 1 | - | 51.94 | 165.6 | 122.9 | 142.6 | 29.48 |
Book Value Per Share 2 | -730.0 | 469.0 | 440.0 | 439.0 | 57.50 | -0.2400 |
Cash Flow per Share 2 | 54.00 | 1.010 | 30.60 | 91.80 | 35.30 | 3.700 |
Capex 1 | 0.03 | - | - | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 2/10/20 | 10/9/20 | 7/9/21 | 3/31/22 | 3/31/23 | 3/25/24 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
-50.94% | 1.7M | |
+2.60% | 108B | |
+8.97% | 105B | |
-0.09% | 23.46B | |
-14.53% | 21.72B | |
-7.05% | 18.64B | |
-38.55% | 17.45B | |
-7.52% | 17.19B | |
+5.76% | 13.99B | |
+36.20% | 12.53B |
- Stock Market
- Equities
- KBLM Stock
- Financials 180 Life Sciences Corp.